Announced Thu, 16 Jul · 12:12 IST
Parmax Pharma files Q1 FY27 dematerialisation compliance certificate
Compliance View source PDF
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+4.0%1-day move
₹97.06
prior close
—
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————+4.0+6.0+8.1+10.3+8.1+8.0————
Up moveDown movePending
AI summary
Parmax Pharma submitted the Regulation 74(5) compliance certificate for quarter ended June 30, 2026. The Registrar (Purva Sharegistry) confirmed that 500 shares held by one shareholder (Ranjanben Gumasana) across five certificates were dematerialised, certificates cancelled, and depository records updated within prescribed timelines. Signed by Managing Director Umang Gosalia.
Likely market impact
Routine procedural compliance filing; no material impact on business, operations, or shareholders.